Lyvgen Biopharma engaged in development of innovative cancer treatment, aims to in-license advanced clinical candidate drugs in order to enrich our pipeline. Please contact us to explore collaboration opportunities.
Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
